Susannah Ludwig

“I guess first on ocular health, cysteine has been a key contributor to growth there with the multi-dose preservative-free unit key driver. I guess could you share roughly what percentage of the cysteine business is now, that multi-dose preservative-free, and how sustainable you see the broader cysteine growth is?”

“I guess my first is just on contact lenses. If you could talk a little bit more on the drivers of growth and the contribution from volume price and the mixed shift to dailies.”

“I guess I wanted to follow up in terms of international IOLs. You guys talked about China. Can you remind us what percentage of your implantables business China is and what your expectations are for the upcoming VBP?”

“And I guess apologies in advance if you've already addressed them. I was on the webcast, and as I highlighted, there was a disruption. But first, we'd be on infusion care, which was the fastest-growing category.”